What are the differences between agonists and antagonists?
Best insight from top research papers
Agonists are ligands that activate intracellular signaling and evoke cellular responses, while antagonists inhibit agonist-stimulated responses by binding to orthosteric or allosteric sites. Full agonists induce maximal responses, while partial agonists cannot induce full responses. Antagonists can behave as partial agonists when the constitutive activity of the GPCR is high, and a partial agonist with weak intrinsic activity may be classified as an antagonist. The relationship between antagonists and partial agonists is complex and influenced by constitutive activity of GPCRs, intrinsic activity, and differences in binding sites. The classification of compounds as agonists or antagonists is not always straightforward due to the multiple aspects of antagonism.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
33 Citations | The paper does not provide information about the differences between agonists and antagonists. The paper is about agonists and antagonists for purinergic receptors. |
| The paper does not provide specific information about the differences between agonists and antagonists. | |
| The paper does not provide information about the differences between agonists and antagonists. | |
3 Citations | The paper discusses the differences between agonists and antagonists. Agonists activate cellular responses, while antagonists inhibit agonist-stimulated responses. |
13 Citations | The paper states that agonists and antagonists have different electron donor-acceptor capacities, with agonists having a similar capacity to dopamine and antagonists having smaller values. |
Related Questions
What are surrogate agonists?4 answersSurrogate agonists are molecules that mimic the function of natural cytokines by binding to specific receptors and initiating signaling pathways. They are designed to overcome the limitations of natural cytokines as therapeutics and provide more selective and targeted effects. Surrogate agonists can be generated by using modular ligands that exploit induced proximity and receptor dimer geometry as pharmacological metrics for high-throughput screening. These molecules can selectively activate certain cell types while avoiding activation of others, allowing for more precise control over immune responses. Surrogate agonists have been developed for various cytokines, including interleukin-10 (IL-10) and interleukin-2 (IL-2), and have shown promising results in promoting cell survival and inducing specific immune responses. They offer the potential to decouple the pleiotropic effects of cytokines and provide new opportunities for targeted therapies in cancer and other diseases.
What are the agonists for GPR27?5 answersAgonists for GPR27 have been identified in several studies. One study reported the first selective GPR27 agonist as 2,4-dichloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (I). Another study identified two compounds, N-[4-(anilinocarbonyl)phenyl]-2,4-dichlorobenzamide and 2,4-dichloro-N-{4-[(1,3-thiazol-2-ylamino)sulfonyl]phenyl}benzamide, as selective surrogate agonists for GPR27. These compounds were found to be selective for GPR27 over its closely related family members GPR85 and GPR173. The most potent agonist identified in the first study was 4-chloro-2,5-difluoro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide. Other agonists with higher efficacies included 4-chloro-2-methyl-N-(4-(N-phenylsulfamoyl)phenyl)benzamide and 2-bromo-4-chloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide. These agonists represent important tools for further characterization of the physiological roles of GPR27.
What are the difference between an inverse agonist and antagonist?5 answersInverse agonists and antagonists are both types of ligands that bind to cell receptors but have different effects. An inverse agonist binds to the receptor and decreases its constitutive activity, resulting in a decrease in basal signaling. On the other hand, an antagonist also binds to the receptor but does not activate it or decrease its constitutive activity. Instead, an antagonist blocks the binding site of an agonist, preventing the agonist from binding and activating the receptor. In summary, an inverse agonist decreases constitutive activity, while an antagonist blocks the binding and activation of an agonist.
How does buprenorphine work as antagonist?5 answersBuprenorphine works as an antagonist by displaying partial mu opioid agonist activity and kappa antagonist activity. This means that buprenorphine can prevent withdrawal symptoms by occupying mu receptors without activating them, while also inhibiting the effects of other opioids if a patient relapses. Additionally, buprenorphine has been found to have kappa antagonist activity, as it produces dose-dependent rightward shifts in the dose-effect curves of the selective kappa agonist U50,488. These findings suggest that buprenorphine acts as an antagonist at the kappa opioid receptor. Overall, buprenorphine's ability to act as both a partial agonist at the mu receptor and an antagonist at the kappa receptor contributes to its effectiveness in treating opioid dependence.
Is cobalt antagonistic with metal chelators?3 answersCobalt can interact with metal chelators, and the effects can vary depending on the specific chelator used. Some chelators, such as EDTA, DTPA, L-cysteine, NAC, and glutathione, have been found to effectively increase the excretion of cobalt and reduce its concentration in tissues, potentially reducing its toxicity. On the other hand, certain cobalt-chelator complexes, such as chloroxine mixed with cobalt ions, have been shown to cause erythrocyte lysis, indicating potential toxicity. Additionally, the interaction between cobalt and chelators can affect the cytotoxicity of bleomycin, with some chelators enhancing its effectiveness while others have no effect. Overall, the interaction between cobalt and metal chelators is complex and can have varying effects on toxicity and therapeutic efficacy.
How to know an antagonist is working well?5 answersAn antagonist is considered to be working well when it is able to bind to the cell receptor through the ligand-receptor process but does not trigger a response. It can either prevent the attachment and function of an agonist or allow the binding but not the appropriate function by blocking the binding site on the cell surface. The affinity, specificity, and selectivity of the antagonist to its receptor or enzyme are important factors in determining its effectiveness. Additionally, the solubility and reversibility of the antagonist should be considered. In the study of competitive receptor antagonism, the use of Schild analysis is preferable to determine antagonist equilibrium constants. It is also important to consider the timescale of events when studying the effects of potent antagonists on synaptic transmission.